Amgen announced that the European Commission has approved a new indication in the Repatha label for adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol levels. With the expanded label now in place, Amgen is working with payers in Europe to remove prescribing barriers and expand access in order to reach patients with established cardiovascular disease who are at risk of another event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.